Skip to main content
Erschienen in: Clinical Rheumatology 3/2021

16.07.2020 | Original Article

Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity

verfasst von: Ling Zhao, Kaisheng Su, Tao Liu, Dejun Sun, Zhenyu Jiang

Erschienen in: Clinical Rheumatology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the relationship of myositis autoantibodies with the diagnosis and severity of idiopathic inflammatory myopathy (IIM) using the 2017 EULAR/ACR idiopathic inflammatory myopathy classification criteria and the myositis disease activity assessment tool (MDAAT).

Methods

Patients who met the new diagnostic criteria were tested for serum myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), and then classified into different subgroups based on autoantibody positivity. Patients were also diagnosed with possible IIM, probable IIM, and definite IIM. The MDAAT was used to evaluate muscular and extramuscular disease activity. The relationships of diagnostic classification with positivity for different myositis autoantibodies were determined.

Results

There were 118 patients, and 81% of them had one or more myositis autoantibody. Anti-Jo-1 was the most common MSA, and anti-Ro-52 was the most common MAA. Sixteen patients (14%) had possible IIM, 36 (31%) had probable IIM, and 66 (56%) had definite IIM. MSA-positive patients were significantly more common in the definite IIM group, but MAA positivity was unrelated to diagnostic classification. Positivity for MSAs or MAAs had no correlations with muscle disease activity. Extramuscular disease activity was greater in MSA-positive than MSA-negative patients, but MAA positivity had no significant association with extramuscular disease activity.

Conclusions

MSA positivity aids in the diagnosis of IIM. MSA positivity was associated with greater extramuscular disease activity. Improving the clinical application of MSAs may enhance the individualized treatment of patients with IMM.
Key Points
• In this paper, we explore the relationships between the myositis autoantibodies and the diagnosis and the disease activity of inflammatory myopathy.
• Positive myositis-specific autoantibodies is associated with the establishment of diagnosis and higher extramuscular disease activity.
• Thus, more extensive application of myositis autoantibodies maybe the key for further disease assessment and research.
Literatur
1.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRef
2.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRef
3.
Zurück zum Zitat Lundberg Ingrid E, Anna T, Matteo B, Werth Victoria P, Clarissa P, de Visser M, Lars A, Amato Anthony A, Barohn Richard J, Liang Matthew H, Singh Jasvinder A, Rohit A, Snjolaug A, Hector C, Cooper Robert G, Katalin D, Dimachkie Mazen M, Feldman Brian M, Ignacio G-DLT, Patrick G, Taichi H, Katz James D, Hitoshi K, Lachenbruch Peter A, Lang Bianca A, Yuhui L, Oddis Chester V, Marzena O, Reed Ann M, Lidia R-S, Helga S, Selva-O’Callaghan A, Yeong-Wook S, Jiri V, Ytterberg Steven R, Miller Frederick W, Rider Lisa G, International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland) (2017) 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. 69:2271–2282 Lundberg Ingrid E, Anna T, Matteo B, Werth Victoria P, Clarissa P, de Visser M, Lars A, Amato Anthony A, Barohn Richard J, Liang Matthew H, Singh Jasvinder A, Rohit A, Snjolaug A, Hector C, Cooper Robert G, Katalin D, Dimachkie Mazen M, Feldman Brian M, Ignacio G-DLT, Patrick G, Taichi H, Katz James D, Hitoshi K, Lachenbruch Peter A, Lang Bianca A, Yuhui L, Oddis Chester V, Marzena O, Reed Ann M, Lidia R-S, Helga S, Selva-O’Callaghan A, Yeong-Wook S, Jiri V, Ytterberg Steven R, Miller Frederick W, Rider Lisa G, International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland) (2017) 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. 69:2271–2282
4.
Zurück zum Zitat Alain M, Béatrice L, Joëlle G, Andoni E-L, Dan L, Laurent A, Thierry M, Eric GJ, Bernard G, Jean S (2018) Inflammatory myopathies: a new landscape. Joint Bone Spine 85:23–33CrossRef Alain M, Béatrice L, Joëlle G, Andoni E-L, Dan L, Laurent A, Thierry M, Eric GJ, Bernard G, Jean S (2018) Inflammatory myopathies: a new landscape. Joint Bone Spine 85:23–33CrossRef
5.
Zurück zum Zitat Anna G, Andrea D (2018) New insights in myositis-specific autoantibodies. Curr Opin Rheumatol 30:614–622CrossRef Anna G, Andrea D (2018) New insights in myositis-specific autoantibodies. Curr Opin Rheumatol 30:614–622CrossRef
6.
Zurück zum Zitat Minoru S, Shin T, Angela C, Calise SJ, Chan Edward KL (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1–19CrossRef Minoru S, Shin T, Angela C, Calise SJ, Chan Edward KL (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1–19CrossRef
7.
Zurück zum Zitat Ran N (2018) Clinical significance of myositis-specific autoantibodies. Immunol Med 41:103–112CrossRef Ran N (2018) Clinical significance of myositis-specific autoantibodies. Immunol Med 41:103–112CrossRef
8.
Zurück zum Zitat Malaviya AN (2018) 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? Ann Rheum Dis 77:e77CrossRef Malaviya AN (2018) 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? Ann Rheum Dis 77:e77CrossRef
9.
Zurück zum Zitat Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54CrossRef Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43:49–54CrossRef
10.
Zurück zum Zitat Aryeh F, Antoniou Katerina M, Brown Kevin K, Jacques C, Corte Tamera J, du Bois Roland M, Lee Joyce S, Leslie Kevin O, Lynch David A, Matteson Eric L, Marta M, Imre N, Luca R, Strek Mary E, Swigris Jeffrey J, Wells Athol U, West Sterling G, Collard Harold R, Vincent C, ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRef Aryeh F, Antoniou Katerina M, Brown Kevin K, Jacques C, Corte Tamera J, du Bois Roland M, Lee Joyce S, Leslie Kevin O, Lynch David A, Matteson Eric L, Marta M, Imre N, Luca R, Strek Mary E, Swigris Jeffrey J, Wells Athol U, West Sterling G, Collard Harold R, Vincent C, ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD (2015) An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:976–987CrossRef
11.
Zurück zum Zitat Clark KEN, Isenberg DA (2018) A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol 25:13–23CrossRef Clark KEN, Isenberg DA (2018) A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol 25:13–23CrossRef
12.
Zurück zum Zitat Evangelia Z, Aliki V, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38:125–132CrossRef Evangelia Z, Aliki V, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38:125–132CrossRef
13.
Zurück zum Zitat Lundberg IE, Anna T (2018) Response to: ‘2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?’ by Malaviya. Ann Rheum Dis 77:e78CrossRef Lundberg IE, Anna T (2018) Response to: ‘2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?’ by Malaviya. Ann Rheum Dis 77:e78CrossRef
14.
Zurück zum Zitat Pisetsky DS (2012) Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol 76:223–228CrossRef Pisetsky DS (2012) Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol 76:223–228CrossRef
15.
Zurück zum Zitat Gapud EJ, Philip S, Brendan A (2017) ANCA—associated vasculitis pathogenesis: a commentary. Curr Rheumatol Rep 19:15CrossRef Gapud EJ, Philip S, Brendan A (2017) ANCA—associated vasculitis pathogenesis: a commentary. Curr Rheumatol Rep 19:15CrossRef
16.
Zurück zum Zitat Elena K, Maria-Louise B-LB, Galina M (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13:175–181CrossRef Elena K, Maria-Louise B-LB, Galina M (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13:175–181CrossRef
17.
Zurück zum Zitat Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420–428CrossRef Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420–428CrossRef
18.
Zurück zum Zitat Targoff IN, Gulnara M, Trieu Edward P, Osvaldo P, Bhanu K, O'Hanlon Terrance P, Miller Frederick W, Rider Lisa G, Childhood Myositis Heterogeneity Study Group, International Myositis Collaborative Study Group (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:3682–3689CrossRef Targoff IN, Gulnara M, Trieu Edward P, Osvaldo P, Bhanu K, O'Hanlon Terrance P, Miller Frederick W, Rider Lisa G, Childhood Myositis Heterogeneity Study Group, International Myositis Collaborative Study Group (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:3682–3689CrossRef
19.
Zurück zum Zitat Manabu F, Yasuhito H, Kenzo K, Takashi M, Yuki I, Masanari K, Naoko I, Ikuko U-H, Yoshihide A, Fumihide O, Keita F, Takuya M, Eriko M, Kenji H, Narihiro A, Naohito H, Kiyohiro T, Akira H, Atsuyuki I, Mariko S, Minoru H, Kazuhiko T (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522CrossRef Manabu F, Yasuhito H, Kenzo K, Takashi M, Yuki I, Masanari K, Naoko I, Ikuko U-H, Yoshihide A, Fumihide O, Keita F, Takuya M, Eriko M, Kenji H, Narihiro A, Naohito H, Kiyohiro T, Akira H, Atsuyuki I, Mariko S, Minoru H, Kazuhiko T (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522CrossRef
20.
Zurück zum Zitat Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN (1999) The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 12:137–142CrossRef Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN (1999) The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 12:137–142CrossRef
21.
Zurück zum Zitat Synnøve ME, Petter RO (2009) Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20:696–704CrossRef Synnøve ME, Petter RO (2009) Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20:696–704CrossRef
22.
Zurück zum Zitat Natalya S, Rekvig OP (2011) Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis. Am J Pathol 179:1120–1128CrossRef Natalya S, Rekvig OP (2011) Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis. Am J Pathol 179:1120–1128CrossRef
23.
Zurück zum Zitat Sandin C, Eriksson P, Segelmark M, Skogh T, Kastbom A (2016) IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis. Clin Exp Immunol 184:208–215CrossRef Sandin C, Eriksson P, Segelmark M, Skogh T, Kastbom A (2016) IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis. Clin Exp Immunol 184:208–215CrossRef
24.
Zurück zum Zitat Shinji S, Akihiro M, Akiko K, Kazuhiko T, Tsuneyo M, Atsushi K, Michiaki M, Takafumi S, Mariko S, Manabu F, Masataka K (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285CrossRef Shinji S, Akihiro M, Akiko K, Kazuhiko T, Tsuneyo M, Atsushi K, Michiaki M, Takafumi S, Mariko S, Manabu F, Masataka K (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285CrossRef
25.
Zurück zum Zitat Jens S (2018) Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5:109–129CrossRef Jens S (2018) Current classification and management of inflammatory myopathies. J Neuromuscul Dis 5:109–129CrossRef
26.
Zurück zum Zitat Apoorva (2019) Dermatomyositis and polymyositis. StatPearls Publishing, Treasure Island Apoorva (2019) Dermatomyositis and polymyositis. StatPearls Publishing, Treasure Island
27.
Zurück zum Zitat Sultan SM, Elizabeth A, Cooper RG, Sangita A, Patrick K, Oddis CV, Jiri V, Lundberg IE, Maryam D, Hanna MG, Isenberg DA (2011) Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 70:1272–1276CrossRef Sultan SM, Elizabeth A, Cooper RG, Sangita A, Patrick K, Oddis CV, Jiri V, Lundberg IE, Maryam D, Hanna MG, Isenberg DA (2011) Interrater reliability and aspects of validity of the myositis damage index. Ann Rheum Dis 70:1272–1276CrossRef
28.
Zurück zum Zitat Lawrence Y, Yip AL, Shrader JA, Sepehr M, Rita V, Jansen AV, Miller FW, Rider LG (2016) Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology (Oxford) 55:441–449 Lawrence Y, Yip AL, Shrader JA, Sepehr M, Rita V, Jansen AV, Miller FW, Rider LG (2016) Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology (Oxford) 55:441–449
Metadaten
Titel
Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity
verfasst von
Ling Zhao
Kaisheng Su
Tao Liu
Dejun Sun
Zhenyu Jiang
Publikationsdatum
16.07.2020
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 3/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05273-3

Weitere Artikel der Ausgabe 3/2021

Clinical Rheumatology 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.